Dow tumbles 600 points as investors dump stocks on inflation and tariff worries: Live updates
Stocks sold off Friday, pressured by growing uncertainty on U.S. trade policy as well as a more grim outlook on inflation.
2025 › March › 28
42 days ago
Assassin's Creed maker Ubisoft reverses gains after Tencent-backed spinoff move
Ubisoft shares surged on Friday after the French video game publisher announced a deal to spin out some of its best-selling franchises.
European shares fall as U.S. core inflation rises more than expected; tariffs remain in focus
European stocks traded lower on Friday as global markets braced for U.S. President Donald Trump's latest tariffs on automakers.
Bangkok declares ‘disaster zone’, at least 144 reported dead in Myanmar after earthquake
found
a story from CNBC › World News
The Stock Exchange of Thailand suspended trading across all exchanges on Friday while Honda and Nissan temporarily halted plant operations.
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.
Assassin's Creed maker Ubisoft reverses gains after Tencent-backed spinoff move
Ubisoft shares surged on Friday after the French video game publisher announced a deal to spin out some of its best-selling franchises.
Investors will be 'miles ahead' if they avoid these 3 things, 'How Not to Invest' author says
Barry Ritholtz's new book discusses why most people are bad at investing, and why famous investors who consistently beat the market are rarities.
Activist investor Elliott takes short position in Shell after building a stake in rival BP
found
U.S. activist investor Elliott Investment Management has taken a short position against British oil major Shell as part of a global hedging program.
Pro Talks: Ways to generate income and survive this volatility, from top money manager Jenny Harrington
found
Jenny Van Leeuwen Harrington, CEO of Gilman Hill Asset Management, joins CNBC's Dominic Chu to discuss her new book, "Dividend Investing: Dependable Income to Navigate All Market Environments." She s…
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.
|← first ← previous page 18 of 69 next → last →|